ArticleAsian Pacific journal of cancer prevention : APJCP2025
Survival Outcomes and Mortality Predictors in Breast Cancer: An Ambidirectional Cohort Study from Central Vietnam.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is one of the most common cancers worldwide; however, there is a lack of comprehensive data on survival outcomes and prognostic factors in Central Vietnam. This study aimed to estimate overall survival (OS) rates and identify key prognostic factors associated with mortality among BC patients in this region.
methodsThis ambidirectional cohort study included 1,213 patients newly diagnosed with BC at Danang Oncology Hospital between January 2019 and December 2023. OS rates at 1, 3, and 5 years were estimated using the Kaplan-Meier method, and survival differences across molecular subtypes and TNM stages were evaluated using the log-rank test. Prognostic factors for mortality were assessed using a multivariable Cox proportional hazards model.
resultsThe 1-, 3-, and 5-year OS rates were 97.4%, 91.0%, and 86.0%, respectively. The Luminal A subtype had the highest 5-year OS rate (91.5%), while the triple-negative subtype had the lowest (76.9%). Patients with stage IV disease had a 5-year OS rate of 29.5%. Significant predictors of higher mortality included unemployment [adjusted hazard ratio (aHR) 1.59], liver diseases (aHR 3.06), progesterone receptor-negative status (aHR 2.20), Ki-67 index ≥30% (aHR 2.13), and TNM stage III-IV (aHR 10.27). Surgical intervention was associated with a reduced risk of mortality (aHR 0.40).
conclusionsThe study found relatively high OS rates in this cohort. However, advanced stage, unfavorable tumor characteristics, comorbidities, and socioeconomic disadvantage were associated with worse outcomes. Collaborative multicenter research using standardized data collection is necessary to validate and expand these findings across diverse settings, ultimately supporting efforts to improve survival outcomes in BC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.